Introduction
Testicular germ cell tumors (TGCTs) are the most common carcinomas of males between the age of 15 and 35 (Schottenfeld et al., 1980) . Cure of TGCTs is possible with cisplatin-based chemotherapy, even in disseminated disease. However, patients refractory to cisplatin-based treatments do exist (reviewed in Dmitrovsky et al., 1990) . Despite recent progress, the molecular basis for germ cell tumorigenesis especially with regard to alterations in tumor suppressor genes and oncogenes is poorly understood (International Testicular Cancer Linkage Consortium, 1998) . The exquisite sensitivity of TGCTs to chemotherapeutic agents, spontaneous dierentiation patterns and characteristic chromosomal abnormalities make them important models of solid tumor biology and embryonic development.
The majority of solid tumors contain p53 mutations (Levine, 1997; Hussain and Harris, 1998) . The loss of p53 function is thought to play a critical role not only in tumor formation, but also in progression and resistance to treatment (Levine, 1997; Hussain and Harris, 1998) . In response to genotoxic stress, p53 is activated. Primarily through its role as a transcription factor, p53 mediates tumor suppression by initiating either cell cycle arrest or apoptosis (El-Deiry, 1998) . The mechanisms mediating p53 activation are poorly understood. Post-translational modi®cations of the p53 protein by DNA damage checkpoint kinases and histone acetyltransferases result in quantitative changes that stabilize p53 or enhance its binding to DNA (Oren, 1999; Meek, 1999; Hirao et al., 2000) . Increased stability occurs primarily through disrupting p53 interactions with mdm2, which functions as a p53 selective E3 ubiquitin ligase (Oren, 1999; Sherr and Weber, 2000) .
A role for the p53 tumor suppressor gene in the etiology and treatment of TGCTs has been proposed (Lutzker, 1998) . TGCTs and derived cell lines often express atypically high levels of p53 protein that are rarely mutated (Peng et al., 1993; Heimdal et al., 1993) . In vitro as well as clinical studies indicate that mdm2 gene ampli®cations are unlikely to contribute to germ cell tumorigenesis (Riou et al., 1995; Lutzker and Levine, 1996) . Recently, a study indicated that overexpressed wild-type p53 was in a latent form in F9 murine teratocarcinoma, suggesting a lack of selective pressure to mutate p53 in TGCTs (Lutzker and Levine, 1996) . Transgenic mice homologously deleted for p53 have a high incidence of spontaneous testicular cancer and targeted over-expression or miss-expression of p53 in mice results in defects in spermiogenesis (Harvey et al., 1993; Schwartz et al., 1999; Allemand et al., 1999) . This, coupled with the fact that p53 expression is restricted to the pachytene stage of meiosis, has led Chaganti and colleagues to propose that the near tetraploid TGCT arises from a meiotically arrested pachytene spermatocyte, which has been aberrantly driven to initiate mitotic cell division (Chaganti and Houldsworth, 2000) .
Retinoids have activity in cancer therapy and prevention (reviewed in Nason-Burchenal and Dmitrovsky, 1999) . The use of retinoids as antineoplastic agents has been limited by vitamin Aassociated toxicity and the ®nding that for many solid tumors (for example, breast and lung cancers) retinoids lose eectiveness during the transition to invasive carcinoma (Armstrong et al., 1994) . This stage of tumorigenesis is associated with increased genomic instability and genetic alterations including mutation or loss of p53 (Levine, 1997) . Clinical studies have shown that aberrant p53 expression in premalignant lesions of the head and neck and oral leukoplakia predicts retinoid resistance (Shin et al., 1997 (Shin et al., , 2000 .
RA-treatment of the pluripotent, human germ cell tumor-derived embryonal carcinoma cell line, NT2/ D1, signals growth suppression, reduced tumorigenicity, and morphologic and immunophenotypic neuronal dierentiation (Miller et al., 1994) . While RA can, under certain conditions, induce an apoptotic response in some malignant cell lines, dierentiation is the dominant response to RA-treatment of NT2/ D1 cells (Kitareewan et al., 1999) . In contrast, the DNA damaging agents etoposide and cisplatin elicit strong apoptotic responses in these cells Arriola et al., 1999) . Mechanisms active in signaling RA eects involve the retinoid receptors: retinoic acid receptors (RARs) and retinoid X receptors (RXRs) (Mangelsdorf et al., 1994; Chambon, 1996) . The identities of target genes which mediate the dierentiation and growth suppressive eects of retinoid-activated RARs are largely unknown. Three RARs (RARa, RARb, and RARg) and three RXRs (RXRa, RXRb and RXRg) exist and have cell context-dependent expression patterns re¯ecting tissue-speci®c retinoid functions and developmental programs (Mangelsdorf et al., 1994; Chambon, 1996) . We previously reported the derivation of an NT2/D1 line designated NT2/D1-R1, which is resistant to RA due to a defect in RARg expression (Moasser et al., 1996; Spinella et al., 1998; Kitareewan et al., 1999) . NT2/D1-R1 cells were derived by brief mutagen treatment followed by prolonged stepwise selection in RA (Moasser et al., 1996) . In the presence of RA, NT2/D1-R1 cells fail to dierentiate, continue to proliferate and retain tumorigenicity (Moasser et al., 1996; Spinella et al., 1999) . Transfection of RARg can partially restore retinoid sensitivity to NT2/D1-R1 cells (Moasser et al., 1995; Spinella et al., 1998) . Engineered overexpression of RARg in NT2/D1 cells also leads to enhanced transcriptional repression of ®broblast growth factor 4 (FGF4), a down-stream target of RA during embryonal carcinoma dierentiation (Moasser et al., 1994; Spinella et al., 1998) .
This study provides evidence that p53 plays an important role in RA mediated terminal dierentiation and cisplatin hypersensitivity of embryonal carcinomas. The ®ndings support a hypothesis that due to the etiology of transformation of the germ line, TGCTs possess additional mechanisms to control p53.
Results

RA-resistant NT2/D1-R1 cells over-express wild-type p53
RA induces neuronal dierentiation with loss of tumorigenicity in NT2/D1 cells. Our prior work revealed that unlike NT2/D1 cells, RA-resistant NT2/D1-R1 cells fail to accumulate in the G1 phase of the cell cycle after RA treatment (Moasser et al., 1996; Spinella et al., 1999) . During an examination of proteins known to regulate the G1 phase of the cell cycle , an unexpected increase in the steady-state levels of p53 was found in NT2/D1-R1 cells as compared to parental NT2/D1 cells ( Figure 1a ). The level of over-expression ranged from 7 ± 10-fold in independent analyses. Levels of p53 were not appreciably changed after RA treatment ( Figure 1a ). This is in contrast to a reported decrease in p53 levels in response to RA in murine F9 teratocarcinoma cells (Lutzker and Levine, 1996) . Since mutant p53 often accumulates to high levels in cells, the mutational status of p53 in NT2/D1-R1 cells was examined. Sequence analysis of cDNA and genomic DNA failed to detect a p53 mutation in either NT2/D1 or NT2/D1-R1 cells. The anti-p53 mutant conformation-speci®c monoclonal antibody, Pab 240, failed to immunoprecipitate p53 from NT2/ D1 or NT2/D1-R1 cells (Figure 1b) . Protein isolated from DAOY cells, which harbor a mutant p53, was used as a positive control. These ®ndings indicate that NT2/D1-R1 cells over-express wild-type p53 tumor suppressor protein despite having a growth advantage in RA, suggesting a defect in p53 signaling in these cells. The defect is not due to dierences in mdm2, since nuclear and total mdm2 levels were similar in both lines (data not shown). This is consistent with previous reports describing overexpressed, wild-type p53 without mdm2 alterations in embryonal carcinoma (Riou et al., 1995; Lutzker and Levine, 1996) .
RA resistant NT2/D1-R1 cells are co-resistant to cisplatin
To further explore the status of p53 in NT2/D1-R1 cells, functional assays were performed with cisplatin, a chemotherapeutic agent that results in curative therapy in male germ cell tumors including embryonal carcinomas. Cisplatin activity is linked to p53 status in diverse cell contexts, including embryonal carcinomas (Lutzker and Levine, 1996; Chresta et al., 1996; Houldsworth et al., 1998; Zamble et al., 1998) . Notably, NT2/D1-R1 cells were 10-fold resistant to cisplatin, as compared to NT2/D1 cells, with an IC-50 value of approximately 1.0 mM, as compared to 0.1 mM for NT2/D1 cells (Figure 2a ). NT2/D1 cells undergo apoptosis in response to cisplatin (Figure 2b ). Upon cisplatin exposure, apoptosis was diminished in NT2/ D1-R1 relative to NT2/D1 cells (Figure 2b ), despite its high basal p53 level. A typical DNA damage stabilization response of the p53 protein with cisplatin or gamma irradiation occurred in NT2/D1 cells ( Figure  3 ). It is clear upon lower exposure to ®lm of these immunoblots that in NT2/D1-R1 cells, the high basal levels of p53 protein increase further with cisplatin and irradiation ( Figure 3 and data not shown). These data suggest that a defect in p53 signaling downstream of p53 stabilization may be present in the NT2/D1-R1 line. The ®nding that RA-resistant NT2/D1-R1 cells are co-resistant to cisplatin is noteworthy since these cells were speci®cally selected for resistance to RA and had no prior exposure to any chemotherapeutic agents, including cisplatin.
RA and cisplatin enhance transactivation properties of p53 in NT2/D1 but not in NT2/D1-R1 cells A transient reporter assay employing a construct containing the p53 responsive promoter-enhancer of the mdm2 gene linked to luciferase was used to assess the transcriptional transactivation properties of endogenous p53 in NT2/D1 and NT2/D1-R1 cells. NT2/ D1 cells had a high basal level of reporter activity relative to NT2/D1-R1 cells (Figure 4) , despite the high levels of p53 in NT2/D1-R1 cells compared to NT2/D1 cells. The reporter activity was induced by both RA (3.5-fold) and cisplatin (twofold) in NT2/D1 cells (Figure 4 ). This was shown to be p53-dependent because a reporter lacking the p53-binding domain had no detected transcriptional activity (data not shown) and because a dominant-negative p53 construct Total protein was isolated from the depicted cell lines and immunoprecipitated (IP) using a mutant conformationspeci®c anti-p53 antibody, p240 and Western analysis performed with a conformation non-speci®c p53 antibody. Total lysates were adjusted to contain the same levels of p53 prior to immunoprecipitation. Only the p53 from DAOY cells, previously con®rmed to harbor a p53 mutation, is recognized by the p240 antibody. Ten per cent of the adjusted lysate used for NT2/D1-R1 and DAOY precipitation was run separately abolished luciferase activity from the mdm-2 reporter ( Figure 6a) . A low level of induction was also seen in NT2/D1-R1 cells. A limitation of transient reporter transfection is that plasmid DNA does not assume the nucleosomal structure of genomic DNA. An impairment in this transactivation potential in NT2/D1-R1 cells was supported by the detected levels of insulin-like growth factor binding protein-3 (IGFBP-3) transcripts, a p53 target gene, upon RA treatment (Figure 4b ). RA induced IGFBP-3 mRNA levels in NT2/D1 cells. This response was greatly diminished in NT2/D1-R1 cells. A similar dierential induction of p21 in response to RA in the two cell lines was observed (data not shown). Together, these data indicate that RA and cisplatin activate p53 transactivation activity in human embryonal carcinoma cells and suggest that p53 induction of transcriptional activity is impaired in NT2/D1-R1 cells.
RA enhances p53 transactivation properties independent of p53 DNA-binding in NT2/D1 but not NT2/D1-R1 cells Activation of p53 can be achieved by events which lead to increased p53 stability, increased p53 DNA binding or events that lead to increased p53 activity, downstream of p53 sequence-speci®c DNA binding. RA did not appreciably aect the steady-state protein level of p53 ( Figure 1 ). To investigate whether RA aects p53 sequence-speci®c DNA binding and to increase the sensitivity of our reporter assays, a monohybrid gal4-based reporter assay was employed. This assay involves co-transfection of a gal4-Luc reporter with a gal4-p53 expression plasmid. Hence, this assay is only sensitive to exogenously transfected p53 and not dependent on the p53 DNA binding domain. The gal-4 system also circumvents potential problems related to proposed promoter-speci®c variations of dierent p53-sensitive target genes. By comparing the activity of gal4-p53 The eect of increasing RA and cisplatin dosages on luciferase activity of an mdm2 based p53 reporter in NT2/D1 versus NT2/D1-R1 cells. Cells were transfected with equivalent levels of pGL2hmdm2-HX-luc and CMV-b-gal reporter plasmids and treated for 48 h with RA (0, .01, 0.1, 1.0, 10 mM) prior to assessing luciferase activity. For cisplatin treatments transfected cells were treated with cisplatin (0, 0.1, 0.5 and 2.0 mM) for 16 h and harvested 32 h later for luciferase activity. A control luciferase reporter lacking the p53-binding site of the mdm2 promoter failed to be induced by RA or cisplatin treatments (data not shown). Each point is the average of three independent determinations. All results were corrected for b-galactosidase activity as described under Materials and methods. Error bars are s.e.m. (b) Eect of RA on transcript levels of the endogenous p53 target gene IGFBP-3 in NT2/D1 and NT2/D1-R1 cells. Induction of IGFBP-3 mRNA transcripts by RA is suppressed in NT2/D1-R1 compared to NT2/D1 cells. RT ± PCR analysis was performed using speci®c primers for IGFBP-3 and b-actin. RT ± PCR assays were performed on RNA isolated from untreated cells or from cells treated with 10 mM RA for the indicated times (hours). Products of the IGFBP-3 PCR reaction were analysed by Southern analysis using an internal IGFBP-3 probe. Products of the actin reaction were stained with ethidium bromide with a construct expressing only gal4, gal4-p53 was shown to have little basal activity in untreated NT2/D1 cells (Figure 5a ). Gal4-p53 speci®c activity increased approximately 20-fold after RA treatment (Figure 5a ).
We con®rmed that RA was not inducing increased p53-DNA binding by employing a gal4-p53 construct in which the entire central core DNA binding domain of p53 was deleted (gal4-p53D117 ± 274). Gal4-p53D117 ± 274 was induced by RA in an identical manner to the wild-type construct (Figure 5b ). Eects of RA on p53 DNA binding were also not detected in gel-shift analysis (data not shown). Cisplatin had no eect on gal4-p53 activity. This may be due to cell loss via cisplatin-induced apoptosis or may indicate that the observed eect of cisplatin relies solely on p53 stabilization and DNA binding eects.
In contrast to NT2/D1 cells, NT2/D1-R1 cells demonstrated no gal4-p53 activity upon RA or cisplatin treatments (Figure 5a ). Our prior work established that RA-resistance in NT2/D1-R1 cells could be reversed after RARg transfection (Moasser et al., 1995; Spinella et al., 1998) . RA-induced gal4-p53 transcriptional transactivation was partially restored in NT2/D1-R1 cells after transfection of RARs, suggesting that the eects of RA on p53 activity are RARmediated ( Figure 5c ). Interestingly, this activity was not apparent in the human immortalized bronchial epithelial cell line HB56-B. This line had high basal p53 activity that was not induced by RA-treatment (data not shown). Co-over-expression of RARs did not rescue RA activation and similar results to those for HB56-B cells were seen in CHO cells (data not shown). These cell types are not induced to dierentiate with RA. Taken together, these data suggest that dierentiation-competent human embryonal carcinomas possess a distinct mechanism that blocks p53 transactivational activity, that is reversed by RA-treatment. The mechanism of RA-activation is at least partially independent of eects on p53 sequence-speci®c DNA binding and is impaired in cells that are resistant to the growth suppressive, dierentiation-inducing and antitumorigenic eects of RA. The evidence suggests that NT2/D1-R1 cells have a defect in an RA-sensitive pathway that stimulates p53 transactivation function. This defect may account for the dual resistance of NT2/D1-R1 cells to RA and cisplatin. Although we have not directly studied the mechanism which accounts for the over-expression of p53 in NT2/D1-R1 cells compared to NT2/D1 cells, we hypothesize that over-expression of p53 is a feedback response in NT2/D1-R1 cells to loss of p53 function. In this regard it should be noted that an alternative explanation for low gal4-p53 activity in NT2/D1-R1 cells could be high endogenous p53 levels which could compete for common coactivators with gal4-p53.
Effect of p53 on a differentiation state-dependent FGF4 reporter assay
The importance of p53 in RA mediated responses in NT2/D1 cells was assessed. A C-terminal fragment of p53, GSE56, which contains the p53 tetramerization domain was employed. GSE56 has previously been shown to inhibit diverse p53 mediated activities in a dominant-negative manner (Ossovskaya et al., 1996) . Eects of RA and cisplatin on gal4-p53 based reporter assay. (a) NT2/D1 and NT2/D1-R1 cells were independently co-transfected with a gal4-Luc reporter and either gal4-p53 (+) or gal4-insertless (7) expression vectors in the presence or absence of increasing dosages of RA (0, 1.0, 10 mM) or cisplatin (0, 0.1, 0.5 mM). RA greatly increases the activity of gal4-p53 in NT2/D1 compared to NT2/D1-R1 cells. (b) The p53 sequence speci®c DNA binding domain is dispensable for RA activation of p53. NT2/D1 cells were co-transfected with a gal4-Luc reporter and either gal4-p53 or gal4-p53 in which the core p53 DNA binding domain is deleted (gal4-p53D117 ± 274) in the presence or absence of increasing doses of RA. RA dosages are the same as in a. (c) Over-expression of RARs partially restores RA-dependent transactivation of p53 in NT2/D1-R1 cells. NT2/ D1 and NT2/D1-R1 cells were transfected as in a in the presence or absence of RA. In addition, NT2/D1-R1 cells were also transfected independently with dierent RAR expression vectors, as indicated. RA dosages are the same as in a. For all transfections each point is the average of three independent determinations. All results were corrected for b-galactosidase activity as described under Materials and methods. Error bars are s.e.m.
This includes the ability to promote immortalization of primary cells, to cooperate with activated ras to transform cells, to confer resistance to etoposide and to inhibit strongly transcriptional transactivation of p53. We previously reported the adaptation of a transient transfection reporter assay to assess rapidly dierentiation-dependent signals in NT2/D1 cells (Moasser et al., 1994; Spinella et al., 1998) . This assay uses a construct containing the human FGF4 promoter-enhancer elements linked to the CAT reporter gene (Yuan et al., 1995) . This RA-and dierentiationsensitive enhancer element contains OCT3/4 and Sox2 sites, but does not contain an RARE. The decline of FGF4 mRNA and protein expression re¯ects eective RA-induced dierentiation and growth suppression of murine teratocarcinomas and human embryonal carcinomas and is`downstream' of direct retinoid receptordriven transactivation in this dierentiation program (Moasser et al., 1994; Yuan et al., 1995; Maerz et al., 1998) . Eects of wild-type p53 and DN-p53 overexpression on FGF4 transcription were studied using this reporter assay. The DN-p53 construct is active in NT2/D1 cells since it abolishes both basal and RAinduced mdm2-Luc activity ( Figure 6a ). As reported previously (Moasser et al., 1994; Spinella et al., 1998) and in Figure 6b , FGF4 reporter activity decreased after RA-treatment in a dose-dependent manner in NT2/D1 cells (an approximate ®vefold decrease). DNp53 greatly stimulates the FGF4-reporter, and substantial activity is still present despite high RA dosages (Figure 6b ). Thus, inhibiting p53 sustains activity of this FGF4-reporter, which is normally only active in undierentiated embryonal carcinoma cells. Overexpression of mdm2, which would independently inhibit p53 function, also stimulates FGF4-CAT activity (Figure 6b ). In contrast, over-expression of wt-p53 inhibits basal activity of this promoter. Eects of modulating p53 on FGF4-CAT activity was shown to depend on the 20 bp dierentiation-sensitive enhancer element contained within the FGF4-reporter. Removal of this element in an otherwise identical plasmid that retains the FGF4 basal promoter was insensitive to DN-p53 or mdm2 over-expression (Figure 6c ). These data indicate that p53 can alter RA-dependent dierentiation responses in NT2/D1 cells. It is unlikely that p53 directly eects RAR signaling since p53 or DN-p53 had no eect on an RAREb2-reporter (data not shown). The data is consistent with p53 playing a role downstream of RAR activation in RA mediated dierentiation responses.
Effects of DN-p53 on NT2/D1 survival after cisplatin treatment An assay was developed to assess the importance of p53 on NT2/D1 cell survival in cisplatin. Cells were transiently co-transfected with either an expression plasmid for b-galactosidase and a DN-p53 expression construct or the b-galactosidase plasmid and an insertless control vector. Each transfection was har- The eect of co-transfection of dominant-negative (DN) p53 on the activity of a p53-sensitive mdm2 luciferase reporter. RA (10 mM) and basal (DMSO) mdm-2 reporter activity is inhibited by co-transfection with a DN-p53 construct demonstrating that DNp53 eectively inhibits p53-dependent transactivation. (b) The eect of DN-p53, mdm2, or wt-p53 on FGF4 promoter-enhancer activity. Expression plasmids for wild-type p53, DN-p53 or mdm-2 were separately co-transfected with the dierentiation-sensitive FGF4-CAT promoter-enhancer reporter. RA treatments were for 48 h at dosages of 0, 0.01, 0.1, 1.0 and 10 mM. Wild-type p53 increases further RA mediated repression of the reporter. DN-p53 and mdm-2 greatly enhances reporter activity in the presence or absence of RA. (c) Eect of p53 alterations on FGF4-CAT activity is dependent on the FGF4 dierentiation-sensitive enhancer. Direct comparison of activities of the FGF4-CAT promoter enhancer used in 7B, FGF4-CAT (+ENH), with an otherwise identical reporter except for the deletion of the 20 bp dierentiation-sensitive enhancer element, FGF4-CAT (7ENH). The FGF4 promoter is intact in FGF4-CAT (7ENH). The eect of wild-type p53, DN-p53 and mdm-2 is dependent on this enhancer element. Each point is the average of three independent determinations. All results were corrected for b-galactosidase activity as described under Materials and methods. Error bars are s.e.m. vested and replated into media containing 0.5 mM cisplatin or control media for 16 h. Cells were stained for b-galactosidase activity 2 days later and positive cells were scored as discussed in the Materials and methods. Results are displayed in Figure 7a . In control cells, there was a 75% reduction in the number of bgalactosidase positive cells after cisplatin treatment. In contrast, there was only a 37% reduction in bgalactosidase positive cells in the DN-p53 co-transfected cells treated with cisplatin. Similar data were obtained by assaying b-galactosidase activity directly from cell lysates of transfectants (Figure 7b ). These data indicate that inhibiting p53 function confers a survival advantage to NT2/D1 cells after exposure to cisplatin.
Discussion
Embryonal carcinomas are quite sensitive to apoptosis induction by DNA damaging agents that may be the basis for the striking curability of human TGCTs . In addition, embryonal carcinomas can undergo terminal dierentiation, with loss of tumorgenicity in response to retinoic acid treatment (Miller et al., 1994; Spinella et al., 1999) . This occurs in vivo in teratoma formation (Hong et al., 1977) . This study focused on the role of p53 in responding to and mediating the eects of dierentiation and apoptosis inducing agents. RA is shown to induce the transactivation activity of p53 in the human embryonal carcinoma cell line NT2/D1. This activation pathway is absent or markedly repressed in RAresistant NT2/D1-R1 cells that express high levels of wild-type p53 as compared to NT2/D1 cells. Notably, it is shown here that NT2/D1-R1 cells are co-resistant to cisplatin mediated apoptosis, demonstrating that defects in p53 activation are linked to aberrant RA and cisplatin responses in this line. We provide evidence that targeted inhibition of p53 alters RA and cisplatin responses in NT2/D1 cells. This implies that pathways that converge on the activation of p53 are required for optimal RA and cisplatin responses, and that common components of these pathways may be disrupted in NT2/D1-R1 cells.
RARg is necessary and required for RA-mediated dierentiation in NT2/D1 cells (Moasser et al., 1995; Spinella et al., 1998) . The current ®nding that restoring RARg expression to retinoid resistant NT2/D1-R1 cells also restores activation of p53 supports the view that RA-dependent activation of p53 is mediated by, and is downstream of, retinoid receptor activation of these cells. It is interesting to note that several distinct RARs partially restored RA-mediated activation of p53 while only RARg restores RA-induced dierentiation and growth suppression to NT2/D1-R1 cells. This may suggest functional redundancy among the RARs in respect to p53 activation when these species are overexpressed. It will be of interest to test whether overexpression of RARg in NT2/D1-R1 cells increases sensitivity to cisplatin. However, interpretation of this experiment is dicult since RARg overexpression by itself growth suppresses NT2/D1-R1 cells (Moasser et al., 1994) . Currently we are developing stable-inducible RARg transfectants to address this issue.
Although RA stimulates the transactivation function of p53, the precise mechanism responsible for this activation needs to be determined. Established pathways of p53 activation that involve increased p53 stability or enhanced site-speci®c DNA binding (Oren, 1999; Meek, 1999; Hirao et al., 2000) do not appear to play a role in the p53 activation response to RAtreatment. We have also failed to detect any gross changes in mdm-2 between NT2/D1 cells and a derived retinoid-resistant line that does not activate p53 in response to RA. That RA failed to induce gal4-p53 in CHO and HB56-B cells despite transfection of RARs argues against a direct physical interaction between p53 and RARs. We have thus far failed to detect a direct interaction between RARs and p53 in mammalian 2-hybrid or co-immunoprecipitation assays. Embryonal carcinomas may have distinct mechanisms to limit p53 activity that are reversed by RA-treatment. Additional cellular contexts will have to be examined to con®rm this hypothesis. A candidate mechanism for cross-talk between p53 and RARs is CBP/p300 which is involved in the transactivation of both transcription factors. RA may modulate the levels of p53-speci®c coactivators or corepressors or aect their interaction with p53 via posttranslational modi®cations. RARs may directly compete with p53 for co-activator binding, although this would be predicted to decrease p53 activity upon sequestration of coactivators by RA bound RAR.
A previous report by Lutzker and Levine (1996) suggested that F9 murine teratocarcinomas harbor latent p53. The current study addresses the mechanism by which RA activates p53. Phosphorylation and acetylation can aect the level and speci®city of p53 binding to DNA and determine which genes are transactivated or repressed (Hecker et al., 1996; Hall et al., 1996) . The heterologous gal4-p53 system used in this study circumvents this issue and suggests that RA stimulates transactivation activity of p53 downstream of DNA binding regardless of the promoter context used. We have performed the gal4-p53 assay in the presence of cycloheximide and monitored luciferase transcripts by RT ± PCR. Interestingly, RA was able to induce gal4-p53 transactivation activity in the presence of cycloheximide (data not shown). The signi®cance of this ®nding awaits further studies. The current study utilizes a patient-derived human TGCT line that may more faithfully re¯ect the biological properties of germ cell tumors than murine teratocarcinoma models (Matin et al., 1998) . While p53 induction by cisplatin appears to be mediated to a large extent by increased p53 stability, it is unclear whether cisplatin can have additional direct eects on p53 transactivation activity that account for cisplatin resistance in the NT2/D1-R1 line. The use of a potent apoptotic inducer in transient reporter assays is problematic due to associated cell loss. Future experiments will be required to clarify this issue.
These functional studies support an important role for p53 in both RA mediated dierentiation and cisplatin-mediated apoptosis. RA, due to its ability to activate RARs, is a regulator of many signaling pathways (Mangelsdorf et al., 1994; Chambon, 1996) . The cellular context of activated p53 in RA-treated embryonal carcinoma versus activated p53 in cisplatin treated cells should vary widely and likely contributes to the opposing biological outcomes of dierentiation and apoptosis. For example, c-myc is highly expressed in undierentiated but not dierentiated NT2/D1 cells (Miller et al., 1990) . Myc over-expression coupled with p53 checkpoint activation has been shown to induce apoptosis (Hermeking and Eick, 1994) . Thus, it is dicult to predict a priori whether dierentiation based therapy would enhance or oppose p53-mediated DNA damaging agents. It has been reported that RA can increase the sensitivity of a murine embryonal carcinoma cell line to etoposide and cisplatin (Guchelaar et al., 1993) . Additional investigations are required to establish a central role for p53 in responses to RA or DNA damaging agents in TGCT.
Based on these ®ndings, we propose RA regulation of a subset of target genes is through activation of p53 which contributes to G1 arrest and subsequent dierentiation. The RA-target genes p21 and IGFBP-3 contain p53 binding motifs in their promoter regions (Liu et al., 1996; Shang et al., 1999) . Both are upregulated after RA-treatment of NT2/D1 cells, while other known p53 targets are not (data not shown). It will be interesting to discover whether a larger subset of p53 targets are regulated by RA and to what extent this pathway contributes to RA-mediated gene regulation.
The unique focus of the current work is the importance of p53 in response to the dierentiation agent RA in TGCTs. Several reports have assessed the importance of p53 in response to DNA damage in TGCTs (Lutzker and Levine, 1996; Houldsworth et al., 1998; Chresta et al., 1996; Zamble et al., 1998; Burger et al., 1997 Burger et al., , 1999 . In vitro experiments with TGCT cell lines suggested a pivotal role for p53 in mediating drug-induced apoptosis (Lutzker and Levine, 1996; Chresta et al., 1996; Houldsworth et al., 1998) . In addition, several clinical studies reveal that TGCTs lack p53 mutations (Peng et al., 1993; Heimdal et al., 1993) . This lack of p53 mutations is consistent with high cure rates found in cisplatin-treated TGCT patients . However, other studies suggest that p53 is not essential for ecient induction of apoptosis in TGCT lines (Burger et al., , 1999 .
Some of these apparent discrepant results may be due to dierences between murine models of TGCT and the human disease (Pera et al., 1990) . Murine teratocarcinomas (and common cell lines such as F9) fail to exhibit many of the genetic, phenotypic, and biologic markers of the human TGCTs (Pera et al., 1990; Matin et al., 1998) . In contrast, NT2/D1 cells were developed from a metastatic lesion of a testicular cancer patient and retain many of these markers including the i(12p) chromosomal marker characteristic of TGCTs (Andrews, 1998) . Mice homozygously deleted of p53 have a higher incidence of testicular cancers (Harvey et al., 1993) . The precipitating transformation event in these mice, loss of the p53 gene, does not occur in human teratocarcinoma. Human teratocarcinoma arises despite high levels of wild-type p53. Presumably p53-dependent checkpoints are compromised in a way other than targeting the p53 protein directly through mutation or loss of expression. Thus, comparing murine teratocarcinoma from wildtype and p53 knockout mice (or teratocarcinoma lines with rare somatic p53 mutations) may not provide information on how p53 is kept in a latent form in human teratocarcinoma, how this latency is reversed by DNA damage or dierentiation induction, and the therapeutic consequences of removing p53 after full malignant transformation has occurred. The current approach, targeting p53 in human embryonal carcinoma cells, may be better suited to address these issues.
In summary, the ®ndings presented suggest the RAmediated activation of the transactivation function of p53 may play a critical role in RA-induced dierentiation. We propose that although this pathway may be prominent in embryonal carcinoma, it may become activated in other retinoid responsive tumor types and tissues, and perhaps after treatment with other dierentiation inducers. Recently, p53 has been implicated as an important protein in embryonic development and in protecting embryos from teratogens (Hall and Lane, 1997; Choi and Donehower, 1999) . Inappropriate over-expression or under-expression of p53 can lead to embryonic lethality or increased risk of malformations (Hall and Lane, 1997; Choi and Donehower, 1999) . RA is a known morphogen and dietary retinoid deprivation or excess results in diverse malformations (Collins and Mao, 1999) . It is possible that the pathway described in the present study plays a role in maintaining the ®ne balance of p53 activity required for optimal progression of developmental programs. RA activation of p53 may represent a critical pathway controlling retinoid-mediated G1 arrest and subsequent dierentiation in gem cell as well as non-germ cell tumors. Insights into the mechanisms involved in p53 latency and activation in the curable TGCT model may impact on novel approaches to treat those common solid tumors that are often refractory to chemotherapeutic agents.
Materials and methods
Cell culture and induction protocols
The RA-sensitive human embryonal carcinoma cell line is a clonal line derived from a xenograft of Tera-2 cells (Andrews, 1998) . Derivation and characterization of the NT2/D1-R1 cell line (an RA-resistant subclone of NT2/D1 cells) has been described elsewhere (Moasser et al., 1995 (Moasser et al., , 1996 Kitareewan et al., 1999) . DAOY is a human cerebellar medulloblastoma cell line harboring a Cys to Phe mutation in codon 242 of p53 (A gift from Dr Nancy Rosen®eld, Memorial Sloan Kettering Cancer Center). Cells were cultured in high glucose DME with 10% fetal bovine serum supplemented with penicillin, streptomycin and glutamine under humidi®ed 5% CO 2 . The RA induction protocols were as follows. On day 71, 1610 5 or 4610 5 cells were seeded into six well plates or 10 cm dishes, respectively. On day 0, medium was replaced with medium containing 10 mM RA or dimethyl sulfoxide (DMSO, 1 : 1000 dilution). We have in the past routinely used 10 mM RA since this dose is optimal for full phenotypic dierentiation of NT2/D1 cells, although a notable response also occurs at 1.0 mM. Embryonal carcinoma cells are known to have high levels of cytosolic retinoic acid binding proteins which may account for the requirement for relatively high doses of RA (Jetten and Jetten, 1979) . Cells could be treated for 6 days before reaching con¯uence under these culture conditions. RA was stored under liquid N 2 in the dark as a 10 mM stock solution in DMSO. For cisplatin treatments, cells on day 0 were exposed to the indicated dosages of cisplatin (Sigma) for 16 h. Cisplatin was then removed and cells were harvested at the indicated time points thereafter. For irradiation experiments, cells were exposed to 2 or 4 Gy of radiation from a 137 Cs source and harvested for Western analysis 24 h later.
Western analysis
Exponentially growing cells were lysed in a modi®ed RIPA buer and analysed by SDS ± PAGE, as described . Protein concentrations were determined using the Bradford technique. Monoclonal p53 antibody (Ab-6) was purchased from Oncogene Research Products. Mutant p53 was immunopuri®ed using the Mutant p53 ImmunoCruz System (Santa Cruz Biotechnology), following the manufacturer's protocol. Cell lysates were ®rst normalized for total p53 by Western analysis using the panatropic Ab-6 antibody. Brie¯y, cleared lysates from approximately 30610 6 NT2/D1 cells or 7610 6 NT2/D1-R1 and 6610 6 DAOY cells were applied to an immunoanity column consisting of the p53 mutant speci®c monoclonal antibody Pab 240, coupled to agarose. Bound protein was eluted and p53 levels were assessed by Western analysis using Ab-6 antibody.
DNA sequence analysis of p53
Exons 2 through 11 of p53 were sequenced using genomic DNA derived from NT2/D1 and NT2/D1-R1 cells, as described (Boyle et al., 2001) . The desired DNA regions were ampli®ed using PCR-based puri®cation of four segments. Sequence analysis was performed using thermosequenase (Amersham) utilizing 33 P-labeled dideoxynucleotide to terminate the PCR reactions. The complete protein coding region of p53 was sequenced from NT2/D1 and NT2/D1-R1 cells. The cDNA was synthesized from total RNA using SuperScript II reverse transcriptase and random primers according to the manufacturer's procedure (GIBCO ± BRL). The entire protein coding region of p53 was ampli®ed as a single DNA fragment. The desired PCR product was gel puri®ed and sequenced, as described above.
Growth and apoptosis assays
NT2/D1 and NT2/D1-R1 cells were seeded at a density of 4610 4 cells per well of a six well plate and the next day exposed to varying concentrations of cisplatin for 16 h. Cells were ®xed and stained 3 days later with Geimsa. In separate experiments, cells were harvested and viable cells directly counted with Trypan blue stain. The percentages of cells that had undergone apoptosis in response to cisplatin were measured using an in situ terminal deoxynucleotidyl transferase (TdT) assay (Boehringer Mannheim) as described (Kitareewan et al., 1999) . Adherent and non-adherent cells were pooled for each of the indicated dosages of cisplatin.
Semi-quantitation of IGFBP-3 mRNA expression by RT ± PCR Expression levels of IGFBP-3 in NT2/D1 and NT2/D1-R1 cells treated with RA were measured by RT ± PCR. The cDNA was synthesized from total RNA using Superscript II reverse transcriptase (GIBCO ± BRL), as previously described Kitareewan et al., 1999) . Ampli®cation of IGFBP-3 and b-actin from the same cDNA was performed using Taq polymerase as described previously Kitareewan et al., 1999) . Experiments were performed to determine the optimal number of cycles that would yield linear phase of ampli®cation. PCR products were resolved on a 1.5% agarose gel stained with ethidium bromide. The IGFBP-3 products were transferred to nitrocellulose and probed with a radiolabeled internal IGFBP-3 primer. Forward and reverse primers for IGFBP-3 were 5'-CGGGCTCTGCGTCAACGCTA-3' and 5'-GTGCTCTGA-GACTCGTAGTCAA-3'. Forward and reverse primers for bactin were 5'-GCGGGAAATCGTGCGTGACA-3' and 5'-AAGGAAGGCTGGAAGAGTGC-3', respectively.
Expression and reporter constructs
The mdm2 reporter plasmid, pGL2hmdm2-HX-luc, contains a 350 bp fragment of the human mdm2 promoter and the intronic p53-sensitive enhancer element in pGL2-Basic (Promega) and was provided by Dr Moshe Oren (Weizmann Institute of Science, Israel). The human gal4-p53 expression and gal4-Luc reporter plasmids were kindly provided by Dr Tucker Collins (Harvard Medical School, MA, USA). The gal4-p53D117 ± 274 expression plasmid, in which the central portion of p53 (amino acids 117 to 274) is deleted was constructed by generating two p53 PCR fragments using gal4-p53 as a template. To facilitate in-frame ligation, a HindIII site was engineered at the junction of the two fragments. This introduced two non-native amino acids at the deleted junction (Ser 116 -Lys-Leu-Cys 275 ). The DN-p53 expression plasmid is based on the dominant negative C-terminal fragment (amino acids 275 ± 368) of rat p53 (GSE56) reported by Ossovskaya et al. (1996) . Brie¯y, using gal4-p53 as template, a PCR fragment was generated which contains an ATG Kozak motif immediately upstream of amino acid 276 of human p53. The fragment of human p53 (amino acids 276 ± 369) was inserted into pcDNA3.1MycHisA (Invitrogen). The mdm2 expression construct was provided by Dr Bert Vogelstein (Johns Hopkins Medical School, MD, USA). The FGF4 reporter, RAR, and CMV-b-galactosidase expression plasmids have been described previously .
Transient transfection reporter assays
The FGF4 reporter assay was previously described (Moasser et al., 1994; Spinella et al., 1998) . Brie¯y, cells were transfected with 5.0 mg DNA including 2.5 mg reporter plasmid, 1.5 mg expression plasmid and 1.0 mg of a CMV driven b-galactosidase expression plasmid using a modi®ed calcium phosphate precipitation technique. The FGF4-CAT construct contains a human RA-sensitive FGF4 enhancer placed within a CAT containing reporter driven by the endogenous human FGF4 promoter (Yuan et al., 1995) . Cells (3610 5 ) were exposed to DNA precipitate for 14 ± 16 h and then to a HEPES buered saline (HBS)/glycerol solution for 45 s. Cells were then washed and cultured with or without RA for an additional 48 h before harvesting in isotonic buer (150 mM NaCl, 40 mM Tris-HCl, pH 8, and 1 mM EDTA). CAT activity was measured as previously reported and was normalized to b-galactosidase activity .
Endogenous p53 transactivation activity was measured using the mdm2-Luc reporter. The mdm2-Luc construct contains the p53 binding element from intron 1 of mdm2 placed within a luciferase containing reporter plasmid driven by the endogenous mdm2 promoter (Zauberman et al., 1995) . Cells were transfected and treated with RA, as described above, using 0.75 mg of mdm2-Luc and 0.5 mg of CMV-b-gal.
For cisplatin induction, cells were treated with cisplatin for 16 h after removal of DNA precipitates. Cisplatin containing media was then replaced with fresh media and cells were harvested 32 h later. Luciferase activity was measured, as previously reported, and was normalized to b-galactosidase activity .
The ability of NT2/D1 and NT2/D1-R1 cells to activate exogenous p53 was assessed upon co-transfection of a gal4-Luc reporter construct and a plasmid expressing the entire p53 protein fused to the gal4 DNA binding protein (Wadgaonkar and Collins, 1999) . A total of 0.5 mg reporter plasmid and 1.0 mg expression plasmid was used per transfection experiment. CMV-b-gal (0.5 mg) was included to normalize for transfection eciency. For all reporter experiments appropriate insertless expression vectors were used as needed to equalize total DNA levels. Plates transfected with a given plasmid combination received a portion of the same calcium phosphate precipitate. Unless otherwise speci®ed, data points represent the average of triplicate transfections with similar results obtained in at least three independent experiments.
Cisplatin survival assays
On day 71, 2610 6 NT2/D1 cells were seeded onto 10 cm dishes. On day 0, the plates were co-transfected with 10 mg of CMV-b-gal and 10 mg of either Myc-HisA insertless expression vector or Myc-HisA containing dominant-negative p53. After 16 h, precipitate was removed from each transfection and an equal number of viable cells (1610 6 ) were replated to two other 10 cm dishes. To one dish, 0.5 mM cisplatin was added. Cisplatin was removed 16 h later and cells were ®xed and stained for b-galactosidase activity 48 h later. Five randomly chosen ®elds of 200 or more cells were scored for each data point. To control for transfection eciency, the per cent positive cells after cisplatin treatment was normalized to its matching untreated control. In all experiments, transfection eciency ranged between 5 and 11%. The data represents the average of three independent determinations. P values were obtained using a two-sided Student's t-test. In separate experiments, transfections were performed in triplicate in individual wells of a 6-well plate using 2 mg total DNA per well. After completion of an identical drug treatment protocol, as described above, cells were lysed directly in reporter assay buer and b-galactosidase activity was then measured by established protocols.
